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Dendritic cells (DCs) are a heterogenous population of bone-marrow-derived immune cells. Although
all DCs share a common ability to process and present antigen to naive T cells for the initiation of an
immune response, they differ in surface markers, migratory patterns, localization, and cytokine pro-
duction. DCs were originally considered to be myeloid cells, but recent findings have demonstrated
that DCs can develop not only from myeloid- but also from lymphoid-committed progenitors. The
common feature of the progenitors capable of developing into DCs is the surface expression of Flt3
receptor. The development of different populations of DCs is differentially regulated by various
transcription factors and cytokines. This review summarizes the recent advances made in the field
of DC development.Introduction
Dendritic cells (DCs) are antigen-presenting cells crucial
for the innate and adaptive immune response to infections
and formaintaining immune tolerance to self-tissues (Ban-
chereau and Steinman, 1998). DCs represent a sparsely
distributed population of bone-marrow-derived cells. Al-
though they share many common features, multiple sub-
types of DCs with distinct life span and immune functions
have been identified (Shortman and Liu, 2002; Shortman
and Naik, 2007). The DC subtypes found in a steady-state
mouse and in human include type-1 interferon-producing
plasmacytoid DCs (pDCs) and the conventional DCs
(cDCs) in the nonlymphoid tissues, in the circulation, and
in lymphoid tissues. The resident cDCs in lymphoid tissues
include cDCs present in the thymus, spleen, and lymph
nodes and consist of phenotypically different subtypes.
cDCs can also be divided into subsets according to
their tissue localizations, such as skin DCs including Lang-
erhan’s cells (LCs) in epidermis and dermal DCs in dermal
areas; mucosal tissue-associated DCs; lymphoid tissue-
associated DCs including splenic marginal zone DCs, T
cell zone-associated interdigitating cells, germinal
center DCs, and thymic DCs; and interstitial tissue DCs
including liver DCs and lung DCs. Tissue microenviron-
ments appear to have major impact on the function of the
residential DCs. In addition, DCs that are not found in the
steady state but develop after infection or inflammation
include the monocyte-derived DCs and the tumor necro-
sis factor (TNF)-producing and inducible nitric oxide syn-
thase (iNOS)-expressing DCs (Geissmann et al., 1998;
Naik et al., 2006; Randolph et al., 1999; Serbina et al.,
2003). Here we review the recent progress on the develop-
ment of DC subsets.
Ontogeny of DCs
In mice, DCs can be detected in the thymus as early as
at embryonic day 17, coinciding with the emergence of
CD4+CD8+ thymocytes and the beginning of thymocyteselection processes. Thereafter, the number of DCs and
thymocytes increases rapidly in parallel. The majority of
cDCs at this early stage are CD8, with the emergence
of CD8+ DC observed at 1 week after birth. The CD8+ pop-
ulation becomes the major population by 2 weeks of age,
with the relative proportions of each subset similar to
those found in the adult thymus (Dakic et al., 2004). The
pDCs appear at the same time as cDCs in the thymus,
and their numbers increase with age and in parallel with
the increase in the number of cDCs.
A substantial number of DCs can be detected in mouse
spleen on day 1 after birth (Dakic et al., 2004; Sun et al.,
2003). The absolute numbers and proportion of both cDC
and pDC do not reach adult amounts until 5 weeks of
age. During this period, the composition of the cDC popu-
lations changed markedly. In contrast to the cDCs found
in an adult spleen that contains the CD8+CD205+ (25%)
and CD8CD205 (75%) populations, in the spleen of a
day 1 newborn mouse, the CD8CD205 cells represent
a minor cDC population, whereas the dominant cDC pop-
ulation is CD8 that also express CD205 (CD8CD205+).
Moreover, this CD8CD205+ cDC subset has the capacity
to produce IL-12p70, a cytokine normally produced by
the CD8+CD205+ cDC in adult spleen (Dakic et al., 2004;
Sun et al., 2003). Interestingly, at 3 weeks of age, the
CD8CD205+ population becomes undetectable and the
CD8+CD205+ cDCs become the major cDC population
with the capacity to produce IL-12p70, although at a rela-
tively lower amount than their adult counterpart, whereas
the CD8CD205 cDCs remain as a minor population.
At the young adult stage (6 weeks), the ratio of the
CD8CD205 and CD8+CD205+ cDCs changes substan-
tially,with theCD8CD205 cDCsbecoming thedominant
population. These phenotypic and functional changes
suggest that the neonatal CD8CD205+ DCs represent an
immature stage of theCD8+CD205+ cDCpopulation found
in adult mouse spleen and that different DC populations
have different developmental kinetics during ontogeny.Immunity 26, June 2007 ª2007 Elsevier Inc. 741
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ReviewsFigure 1. A Developmental Scheme
of Mouse DC Development from
BM Hemopoietic Stem Cells and
Lineage-Committed Progenitors
Both cDC and pDC can be generated from the
Flt3 expressing early myeloid or lymphoid pro-
genitors. Flt3L is essential for the development
of steady-state DC populations. Under inflam-
matory conditions, i.e., in the presence of
GM-CSF, monocytes can differentiate into
cDC. Abbreviations: HSC, hemopoietic stem
cell; MPP, multipotent progenitors; CMP,
common myeloid precursors; CLP, common
lymphoid precursors; GMP, granulocyte and
macrophage precursors; MEP, megakaryo-
cyte and erythrocyte precursors; M-DC, mac-
rophage and DC precursors.Consistent with the developmental kinetics of DC during
mouse ontogeny, functional analysis of neonatal DC
have shown that they are immature in a number of different
functions including cytokine production and antigen
presentation (Dakic et al., 2004; Muthukkumar et al.,
2000; Ridge et al., 1996; Sun et al., 2003; Vollstedt et al.,
2003).
In humans, MHC class II-expressing DC-like cells can
be detected in the yolk sac and mesenchyme as early as
4–6 weeks of gestation, which preceded the formation of
liver, bone marrow, and thymus (Janossy et al., 1986).
These MHC class II-expressing DC-like cells appear in
the thymic medulla and paracoritcal area of mesentery
lymph nodes at 11–14weeks, nonlymphoid tissues except
brain at 12 weeks, bone marrow at 14–17 weeks, the T
zone of spleen at 16 weeks, and fetal skin and tonsillar
crypts at 23 weeks of gestation (Janossy et al., 1986; Hof-
man et al., 1984). Little is known on the ontogeny of human
pDCs, although pDCs can be detected in fetal thymus and
liver (Y.-J.L., unpublished observation).
Myeloid Origin of DC
DCs were originally considered to have a myeloid origin.
Early studies demonstrated that mouse BM myeloid pre-
cursors had a capacity to producemacrophages, granulo-
cytes, and DCs in the presence of granulocyte-macro-
phage colony-stimulating factor (GM-CSF) (Inaba et al.,
1993). Similar development was found in the studies of
human cells where a CD34+ BM-derived precursor differ-
entiated into CD1a monocytes, a granulocyte-precursor
population, and a bipotential precursor population with
the ability to produce mature DC when cultured in the
presence of GM-CSF and TNF-a or macrophages when
cultured in the presence of M-CSF (Reid et al., 1992; Sza-
bolcs et al., 1996; Caux et al., 1996). Further evidence for
a myeloid origin of DC came from the finding that mono-742 Immunity 26, June 2007 ª2007 Elsevier Inc.cytes differentiate into DCs in the presence of GM-CSF
and IL-4, in vitro (Romani et al., 1994; Sallusto and Lanza-
vecchia, 1994; Akagawa et al., 1996; Kiertscher and Roth,
1996; Pickl et al., 1996; Zhou and Tedder, 1996; Chapuis
et al., 1997). This differentiation process also occurs
in vitro when monocytes reverse transmigrate in an
ablumenal-to-lumenal direction across endothelial cells
(Randolph et al., 1999). A similar phenomenon has been
observed in vivo with subcutaneous tissue monocytes
(Figure 1; Randolph et al., 1999).
Direct evidence for a myeloid origin of DC came from
studies demonstrating that the transplantation of mouse
BM common myeloid progenitors (CMPs) into irradiated
recipients led to the reconstitution of the cDCs and pDCs
in the spleen and thymus (Traver et al., 2000; Wu et al.,
2001; Manz et al., 2001a). Further studies demonstrate
that the CMPs are heterogenous in Flt3 expression, and
it is the Flt3+ fraction of CMPs that is able to produce all
cDC and pDC subsets found in the mouse spleen and
thymus (Figure 1; D’Amico and Wu, 2003). In addition, a
CX3CR1
+CD117+ clonogenic progenitor that can give rise
to macrophages and splenic-resident cDCs but not pDC
has been identified from mouse BM (Fogg et al., 2006).
This progenitor may represent a common precursor for
macrophage and cDCs downstream of the CMP and the
branch point of pDC differentiation.
Lymphoid Origin of DC
Early studies on the lymphoid tissue-resident DCs demon-
strate that thymic cDCs and subpopulations of cDC in
mouse spleen and LNs express markers associated with
lymphoid cells, includingCD8a, CD4,CD2,BP1, andCD25
(Vremec et al., 1992). This finding suggests that someDCs
may have a lymphoid origin. The first direct evidence for
a lymphoid origin was provided by studies showing that
the transfer of intrathymic lymphoid-restricted precursors
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give rise to both T cells and CD8+ thymic cDCs (Figure 1;
Wu et al., 1995; Ardavin et al., 1993). This precursor was
also shown to have the potential to produce both CD8+
and CD8 splenic cDC when injected intravenously and
to be devoid of myeloid potential (Wu et al., 1996, 2001;
Martin et al., 2000). Subsequent studies of the mouse
BM common lymphoid progenitor (CLP) also demonstrate
the potential of these progenitors to differentiate into DCs
both in vitro and in vivo (Wu et al., 2001;Manz et al., 2001b;
Izon et al., 2001). Although a bias toward producing the
CD8+ DC population was observed, the CLP displayed
the capacity to give rise to all splenic and thymic DC sub-
sets (Wu et al., 2001; Dakic andWu, 2003). Thus, evidence
for a lymphoid origin of DCs has been firmly established.
The fact that both the CMP and CLP are capable of
giving rise to all DC subtypes of the spleen and thymus
not only demonstrates that DCs can be of either myeloid
or lymphoid origin, but also indicates that the phenotype
of the DCs is not a reflection of its lineage origin.
Origin of pDCs
It was initially suggested that pDC (also known as inter-
feron-producing cell, IPC) is of lymphoid origin, based
on the finding that human pDCs express many lymphoid
markers, including germline IgK and pre-T cell receptor
(Grouard et al., 1997; Rissoan et al., 1999) but do not ex-
press myeloid markers. In addition, mouse pDCs were
found to express the Rag gene and harbor IgH D-J rear-
rangement (Corcoran et al., 2003; Shigematsu et al., 2004;
Pelayo et al., 2005). Two separate studies further support
the lymphoid origin of pDC in human andmice. First, over-
expression of the dominant-negative transcription factors
Id2 or Id3 in human CD34+ hematopoietic progenitor cells
blocks development of pDC, T cells, and B cells, but not
myeloid DC (Spits et al., 2000). Second, knockdown of
Spi-B, a hematopoietic-specific Ets family transcription
factor that is expressed exclusively in lymphoid cells, in
human CD34+ hematopoietic progenitor cells strongly
inhibits their potential to differentiate into pDC (Schotte
et al., 2004). However, more recent studies revealed that
Flt3+ cells within either CLPs or CMPs could differentiate
into both cDC and pDC in cultures and in vivo (D’Amico
and Wu, 2003; Chicha et al., 2004; Shigematsu et al.,
2004). An interesting observation from the study of Shige-
matsu et al. was that although Rag expression and IgHD-J
rearrangements were not detectable in CMPs, CMP-
derived pDCs express both Rag and IgH D-J rearrange-
ment. The authors suggest that the expression of Rag
and IgH D-J rearrangement does not necessarily reflect
pDC lineage origin but is a result from the ‘‘ectopic expres-
sion’’ or ‘‘reactivation’’ of Rag and IgH D-J rearrangement
during CMP differentiation into pDCs. Alternatively, be-
cause CMPs contain the Flt3+ progenitor population that
is capable of differentiating into pDC, cDCs, and more in-
terestingly B cells (D’Amico and Wu 2003), the pDCs de-
rived from the Flt3+ fraction of CMPs could be the progeny
of the precursorswith potential for both pDC andBcell dif-
ferentiation. If this is indeed the case, the question will bewhere pDC, cDC, and B cells branch out from the Flt3+
progenitors, and what regulates this divergence.
Development of DC from the Immediate
Precursors
A precursor that is at a developmental stage just before the
formation of a phenotypically identifiable DC is termed im-
mediate DC precursor. These precursors can be identified
and isolated frommousebloodandhaveacapacity todiffer-
entiate intomature subsets of DCs in vitro. Twopopulations
of DC precursors in mouse blood have been described
(O’Keeffe et al., 2003). The CD45RACD11cintCD11b+
population represents immature cDC that acquires the
morphology of mature cDCs in the presence of TNF-a and
the ability to stimulate T cells and to produce IL-12 in re-
sponse to microbial stimuli. The CD45RA+CD11cloCD11b
population represents the pDCs. These cells mature into
cDC-like cells only in the presence of stimuli such as CpG
andGM-CSF,weakly stimulate T cells in thismatured state,
and produce large quantities of type I interferon (Nakano
et al., 2001; Martin et al., 2002; Asselin-Paturel et al.,
2001). Thus, although this precursor DC population is able
to differentiate into a cDC-like population of cells, their
poor antigen-presenting capabilities make them distinct
from the mature cDCs (Krug et al., 2003).
The DCs in peripheral lymphoid organs are continually
replaced by blood-borne precursors. A recent study re-
ported that DCs inmouse spleen and LNs underwent a lim-
ited number of cell divisions in situ and could be entirely
replaced within 10–14 days (Liu et al., 2007). Consistent
with this finding, in situ cDC precursors (pre-DCs) with
limited proliferation potential have been identified in
mouse spleen and lymph nodes (Naik et al., 2006; Diao
et al., 2006). These precursors were identified in mouse
spleen as CD11cintCD45RAloCD43intSirp-aintCD4CD8
and comprised 0.05% of splenocytes (Naik et al., 2006).
When transferred into nonirradiated recipient mice, they
differentiated into all splenic cDC populations with limited
proliferation within 3–5 days, representing themost imme-
diate cDC precursors identified to date. These pre-DCs
are distinct from monocytes, because transfer of purified
monocytes into a steady-state mouse did not generate
significant number of cDC in the spleen. Monocytes can
differentiate into splenic cDC only under a GM-CSF-medi-
ated inflammatory condition (Naik et al., 2006). There are
two major monocyte subsets that vary in chemokine re-
ceptor (CCR) and adhesion molecule expression and in
migratory and differentiation properties. In humans, ‘‘clas-
sical’’ CD14+CD16 monocytes express CCR2, CD64,
and CD62L, whereas ‘‘nonclassical’’ CD14loCD16+ mono-
cytes lack CCR2. Their counterparts in mice are
CCR2+Gr-1hi and CCR2Gr-1lo monocytes, respectively.
Gr-1hi (Ly6Chi) monocytes are recruited to inflammatory
sites, e.g., inflamed skin or acutely inflamed peritoneum,
and give rise to macrophages and DCs in inflammatory
or infectious disease models and to epidermal LCs after
skin inflammation. Gr-1lo monocytes have been proposed
as precursors for steady-state DCs, but experimental ev-
idence is as of yet limited (Tacke and Randolph, 2006).Immunity 26, June 2007 ª2007 Elsevier Inc. 743
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cDCs
DC Populations CD4CD8+ CD4+CD8 CD4CD8 pDCs LCs
Ikaros + + + + 
IRF-2  + +  +/
IRF-4  + +/ +/ nd
IRF-8 +   + +/
PU.1 +a +a +a +a nd
Id2 +  +/  +
RelB  + +/ a 
STAT3 + + + nd nd
Gfi1 + + + + 
The requirement of transcription factor for the development of each DC populations is presented as follows: +, required; ,
not required; +/, partially required; and nd, not determined.
a A. Dakic, S. Nutt, and L.W., unpublished observations.Transcription-Factor Regulation
of DC Development
Given that bothmyeloid and lymphoid precursors have the
capacity to generate all lymphoid-resident DC subsets,
the following questions still remain: how are the individual
subsets delineated, and at what point in DC development
is the commitment made to a subpopulation of DC? These
questions have been partially addressed by studies on the
roles of transcription factors in DC development. Growing
evidence indicates that distinct DC subpopulations require
different transcription factors during ontogeny (Table 1).
The zinc finger transcriptional regulator Ikaros has been
shown to play an essential role in DC development. Al-
though a dominant-negative mutation in the Ikaros gene
in mouse led to the ablation of all DC subsets, a null muta-
tion in the Ikaros gene showed an absence of CD8 cDC
and pDC and residual CD8+ cDC development (Wu et al.,
1997; Allman et al., 2006). These studies demonstrate a
requirement for Ikaros for the development of most cDC
and pDC, which is consistent with the observation that
Ikaros is required for the normal development of the early
hemopoietic progenitors (Nichogiannopoulou et al., 1999).
The first transcription factor identified as being impor-
tant in subset delineation was RelB. RelB is a member of
the NF-kB (Rel) family and was found to be expressed at
higher amounts in CD8 cDC compared to CD8+ cDC in
the spleen. Disruption of RelB gene resulted in the defec-
tive development of cDCs, especially the splenic
CD4+CD8 DC subset, but not the CD4CD8+ and
CD4CD8 DCs (Weih et al., 1995; Burkly et al., 1995;
Wu et al., 1998; L.W., unpublished data). Consistent with
these observations, mice lacking the TRAF6 transcription
factor, believed to act upstreamof the same signaling cas-
cade of RelB, also show defects in CD4+CD8 cDC devel-
opment (Kobayashi et al., 2003).
The three interferon regulatory factors (IRF), namely
IRF-2, IRF-4, and IRF-8 (also known as ICSBP), also play
important roles in the development of different DC popula-744 Immunity 26, June 2007 ª2007 Elsevier Inc.tions. Mice lacking a functional IRF-2 or IRF-4 gene
showed defects in the development of CD4+CD8 cDC,
and IRF-4-deficient mice also showed defect in pDC sub-
sets in the spleen (Suzuki et al., 2004; Ichikawa et al., 2004;
Honda et al., 2004). In contrast, IRF-8 plays crucial roles in
the development and function of CD4CD8+ cDCs, pDCs,
and LCs (Schiavoni et al., 2002, 2004). Further studies on
micewith double deficiencies of IRF-4 and IRF-8 showde-
fects in the development of all DC populations, suggesting
a nonredundant role of each of the factors in the develop-
ment of specific DC subsets (Tamura et al., 2005). Al-
though these studies demonstrate the importance of these
IRFs inDCdevelopment, further investigation is required to
elucidate the molecular mechanisms.
Id2, a member of the inhibitory helix-loop-helix (HLH)
transcription factor family, is upregulated during DC de-
velopment and is required for the development of
CD4CD8+ cDCs and LCs (Hacker et al., 2003). In con-
trast, overexpression of Id2 in hemopoietic stem cells
inhibited the development of pDCs, indicating that Id2
acts as an inhibitor of pDC development (Spits et al.,
2000). This inhibitory effect of Id2 in pDC development
may be mediated by antagonizing the functions of activat-
ing HLH factors HEB and E2A, as indicated by the fact that
overexpression of these factors in hemopoietic progeni-
tors stimulated pDC development (Schotte et al., 2004).
The ETS transcription factor Spi-B is expressed by pDCs,
B cells, and CD34+ hemopoietic progenitors, but not by
cDCs. The knockdown of Spi-B mRNA expression in hu-
man hemopoietic progenitors led to the defective devel-
opment of pDCs, but stimulated the development of B
cells and myeloid cells. These findings demonstrated
that Spi-B functions as a key regulator of pDC develop-
ment (Schotte et al., 2004). The transcription factor
PU.1, another member of the ETS family that interacts
with Spi-B, IRF-4, and IRF-8, is also required for the devel-
opment of both cDCs and pDCs, as shown by the fact that
impaired development of cDCs from the hemopoietic
Immunity
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mice (Guerriero et al., 2000; Anderson et al., 2000) and de-
fective development of both cDCs and pDCs in the adult
mice with induced deletion of PU.1 have been observed
(A. Dakic, S. Nutt, and L.W., unpublished data).
Distinct molecular-signaling pathways for the develop-
ment of steady-state DC and the inflammation-induced
DC differentiation have recently been distinguished. The
transcription factor STAT3 is required for Flt3L-dependent
steady-state DC development. Deletion of STAT3 in he-
mopoietic cells abolished the effects of Flt3L on DC devel-
opment and led to a profound deficiency in the DC com-
partment in lymphoid tissues. In contrast, deletion of
STAT3 did not affect DC development in vitro in the pres-
ence of GM-CSF, indicating that STAT3 is not required for
GM-CSF-dependent inflammatory DC differentiation
(Laouar et al., 2003). Moreover, the transcriptional repres-
sor Gfi1 has been shown to control DC development
through regulating STAT3 activation. Gfi1-deficient mice
showed a global reduction of myeloid- and lymphoid-de-
rived DCs in all lymphoid organs, whereas epidermal LCs
were enhanced in number (Rathinam et al., 2005). Gfi1
also functions as a critical modulator of DC versus macro-
phage development (Rathinam et al., 2005).
Cytokine Regulation of DC Development
In addition to the transcription factors that differentially
regulate the development of distinct DC subsets via differ-
ent signaling pathways, several cytokines have been
shown to differentially promote the growth and differenti-
ation of different DC subsets. As mentioned above, Flt3L
is a crucial factor in both human and mouse for promoting
the development of both cDC and pDC in vivo and in vitro.
However, a bias toward the generation of CD8+ cDC and
pDC in the spleen has been observed in mice treated
with murine Flt3L (O’Keeffe et al., 2002b; Bjorck, 2001).
In contrast, treatment of mice with GM-CSF, a cytokine
that promotes the differentiation of myeloid DC from the
early hemopoietic progenitors and monocytes, promoted
the development of the splenic CD8 cDC (O’Keeffe et al.,
2002b). Studies have also shown that although GM-CSF
and Flt3L both play a critical role in the development of
cDC, only Flt3L is critical for the development of pDCs.
In addition, GM-CSF promotes cDC development at the
expense of pDC development mediated by Flt3L in vivo
and in vitro (Maraskovsky et al., 1996; Pulendran et al.,
2001; Blom et al., 2000; Gilliet et al., 2002; Naik et al.,
2005). GM-CSF requires STAT5 to suppress Flt3L-driven
pDC development from the linFlt3+ bone-marrow pro-
genitor population. In vivo, STAT5-deficient hematopoi-
etic progenitors repopulate the pDC lineage preferentially
relative to STAT5-sufficient progenitors. In contrast,
STAT5 is necessary for maximal reconstitution of cDCs.
STAT5 activation by GM-CSF rapidly attenuates the
expression of critical pDC-related genes in linFlt3+ bone-
marrow progenitor cells cultured in Flt3L. GM-CSF there-
fore controls pDC development through a STAT5-depen-
dent pathway that impinges upon the pDC transcriptional
network, influencing the production of DC subsets fromthe progenitor compartment (E. Esashi, Y.-H. Wang, O.
Perng, X.-F. Qin, Y.-J.L., and S.S. Watowich, unpublished
data).
The cytokine TGF-b1 plays a critical role in LC develop-
ment as demonstrated by the fact that the in vitro genera-
tion of LCs from CD34+ progenitors can be greatly
enhanced by TGF-b1 (Caux et al., 1999). The TGF-b1-
deficient mice lacked LCs (Borkowski et al., 1996), but
BM cells from TGF-b1-deficient mice could give rise to
LC after transfer into lethally irradiated recipients. Thus,
the LC defect in TGF-b1-deficient mice is not a result of
deficiency in BM LC precursors; instead, TGF-b1 pro-
duced by non-BM-derived cells is required for the differ-
entiation of LCs (Borkowski et al., 1997). It has been sug-
gested that TGF-b1 exerts its effect through regulating the
expression of its downstream transcription factor Id2,
which is required for the normal development of LCs
(Zenke and Hieronymus, 2006).
Organ-Specific DC Populations in the Thymus
The thymus is aprimary lymphoid tissuewhere T cell differ-
entiation and selection occurs and leads to the generation
of naive CD4+ and CD8+ T cells with a diverse TCR re-
pertoire, naturally occurring CD4+CD25+ regulatory T cells
(Apostolou et al., 2002; Jordan et al., 2001; Watanabe
et al., 2005), as well as some of the double-negative invari-
ant T cell subsets, such asNKT cells (Benlagha et al., 2005;
Tilloy et al., 1999) or mucosa-associated invariant T (MAIT)
cells (Treiner et al., 2003). Thymus is also the site for central
immune tolerance induction. Mouse thymus contains
CD11cintCD45RA+ pDCs and two CD11chiCD45RA cDC
subsets that can be segregated on the basis of CD8 and
the signal regulatory protein-a (Sirp-a) expression, as
CD8+Sirp-a and CD8/loSirp-a+ cDC subsets (Lahoud
et al., 2006). The CD8+Sirp-a subset representing
70% of thymic cDC is generated within the thymus
from the earliest intrathymic progenitors, whereas the
minor CD8/loSirp-a+ cDC subset is originated from the
peripheral migratory DCs (Donskoy and Goldschneider,
2003; A. Proietto and L.W., unpublished data). Similarly,
human thymus also contains pDCs and two subsets of
mature CD11c+ cDC: CD11bCD45ROlo DCs that lack
myeloid markers and a minority of CD11b+CD45ROhi
DCs expressing many myeloid markers (Bendriss-
Vermare et al., 2001; Vandenabeele et al., 2001). Thymic
pDCs were shown to produce type I IFN in HIV-1-infected
thymus, which exerts antiviral effects (Gurney et al., 2004)
and upregulates MHC class I expression on thymocytes
(Keir et al., 2002). Whether thymic pDC play a role in the
differentiation and/or selection of T cell subsets is unclear.
Thymic cDC, although sharing many common features,
differ from other peripheral DC subsets in that the majority
of thymic cDCs in mouse is derived from an intrathymic
precursor, suggesting a nonmigratory behavior (Ardavin
et al., 1993; Wu et al., 1995, 1996), and they mostly pres-
ent self-Ag rather than foreign Ag (Steinman et al., 2003).
Thymic cDCs play important roles in the induction of cen-
tral tolerance through the process of negative selection
(Gao et al., 1990; Brocker et al., 1997; GoldschneiderImmunity 26, June 2007 ª2007 Elsevier Inc. 745
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et al., 2006) as well as the generation of the naturally
occurring CD4+CD25+ regulatory T cells (Watanabe et al.,
2005; A. Proietto and L.W., unpublished data).
Organ-Specific DC Populations in the Spleen
The spleen is a rich source of lymphoid tissue-resident
DCs. The DC populations in mouse spleen have been
well characterized. Three cDC subsets have been identi-
fied in the mouse spleen based on the surface expression
of CD8a and CD4, in addition to high levels of CD11c ex-
pression on all cDCs. These cDC subsets are CD4CD8+,
CD4CD8, and CD4+CD8 (Vremec et al., 2000). The
CD4CD8+ cDCs also express CD205, but not Sirp-a. In
contrast, the CD4CD8 and CD4+CD8 cDCs do not
express CD205, but are Sirp-a+ (Vremec et al., 2000;
Lahoud et al., 2006). The CD8CD205 cDCs are located
in the marginal zone, whereas the CD8+CD205+ cDCs are
in T cell areas (De Smedt et al., 1996). Marginal-zone DC
can rapidly migrate into the T cell zone after LPS stimula-
tion (De Smedt et al., 1996). Cell kinetic study via BrdU
administration revealed that the splenic cDCs have a rapid
turnover rate, with most of the cDCs turning over within
3 days. This study also revealed that the three cDC
subsets represent products of separate developmental
lineages rather than different maturation states of one
cell lineage (Kamath et al., 2000). A significant number of
splenic cDC can be generated in situ by the intrasplenic
immediate cDC precursors (Naik et al., 2006; Diao et al.,
2006).
In addition to the cDCs, pDCs are also found in mouse
spleen. They are defined as CD11cintCD45RA+B220+.
Similar to the blood pDC, the freshly isolated splenic
pDC do not have the phenotypic and functional features
of the antigen-presenting cDC, but can assume a cDC
morphology and upregulate the cDC markers CD11c and
MHC class II after activation with microbial stimuli. They
represent the major cell type that produce large amounts
of type-1 interferon, a cytokine involved in innate immunity
to virus (Siegal et al., 1999; Asselin-Paturel et al., 2001;
Nakano et al., 2001; O’Keeffe et al., 2002a; Bjorck, 2001).
Themost likely origin of pDC in the spleen is the peripheral
blood, because cells with the characteristics of pDC can
be found in mouse blood, and the intrasplenic DC precur-
sors do not differentiate into pDC (O’Keeffe et al., 2003;
Naik et al., 2006).
A newly identified DC lineage, namely interferon-
producing kill DC (IKDC), has also been found in mouse
spleen. These IKDCs have a molecular expression
profile of NK cells and DCs with a phenotype
CD11c+NK1.1+B220+ (Taieb et al., 2006; Chan et al.,
2006). Upon activation by various stimuli, IKDCs can pro-
duce large amount of IFN-g and kill typical NK target cells
and display some antigen-presenting cell activity (Chan
et al., 2006). Like NK cells, the development of IKDC re-
quires Id2, but the major precursor population for IKDC
appears to be the LinSca-1+c-KithiThy1.1L-selectin+
lymphoid progenitors (LSP) rather than CLPs (Welner
et al., 2007). It is therefore suggested that IKDC may arise746 Immunity 26, June 2007 ª2007 Elsevier Inc.from a unique differentiation pathway that diverges early
from those responsible for NK, pDC, T, and B cells.
The studies of splenic DC populations in human have
been hampered by the limited tissue sources. One
study reported that human splenic DCs were located in
marginal zone, T cell, and B cell areas with a phenotype
of CD11c+HLA-DQ+CD1aCD4+CD11bloCD16CD54+
(McIlroy et al., 2001). However, it is not clear how these
DC correlate functionally with mouse splenic DC subsets
or with the human blood DC subsets.
Organ-Specific DC Populations in Lymph Nodes
The DC populations found in mouse LNs are more com-
plex. In addition to the three phenotypically and function-
ally equivalent cDC populations found in mouse spleen,
two additional subpopulations have been described (Henri
et al., 2001; Hochrein et al., 2001). These correspond to
themature CD8loCD205int andCD8loCD205hi cDC thatmi-
grate from the dermis and epidermis, respectively, to the
LNs. Subcutanous LNs contain a higher percentage of
the CD8loCD205hi LC-like cells than the mesenteric LNs
(Henri et al., 2001). The migratory LC-derived DCs are re-
sponsible for carrying antigens picked up from periphery
to the draining LNs.
Organ-Specific DC Populations in Skin
Human CD34+ hemopoietic progenitors differentiate into
both LCs and dermal DCs in culture with GM-CSF and
TNF-a (Caux et al., 1992). CD34+ progenitors differentiate
into common lymphoid progenitors (CLPs) and common
myeloid progenitors (CMPs). CMPs appear to differentiate
into CLA+ (cutaneous lymphocyte antigen) and CLA
populations, which subsequently differentiate into
CD11c+CD1a+ and CD11c+CD1a DC, respectively
(Strunk et al., 1997). Whereas CD11c+CD1a+ DCs migrate
into the skin epidermis and become LCs, CD11c+CD1a
DCsmigrate into the skin dermis and other tissues and be-
come interstitial DCs (Ito et al., 1999). As described above,
TGF-b plays a critical role in LC development as demon-
strated by the fact that the in vitro generation of LCs
from CD34+ progenitors can be greatly enhanced by
TGF-b (Caux et al., 1999), and TGF-b-deficient mice lack
LCs (Borkowski et al., 1996, 1997). More recent studies
further demonstrated that Flt3+ CMPs as well as mono-
cytes could all give rise to LCs in vivo (Mende et al., 2006;
Ginhoux et al., 2006). These studies suggest that both
LCs and dermal DCs belong to the myeloid DC lineage.
DC Populations in Blood
Human DC subsets in the blood are well characterized be-
cause of tissue accessibility. Human blood contains two
types of DC precursors, monocytes and pDC, which can
be induced to differentiate into DCs after ex vivo culture
(Grouard et al., 1997; Rissoan et al., 1999; Sallusto and
Lanzavecchia, 1994). In addition, human blood contains a
subset of immature CD11c+ myeloid DC (O’Doherty et al.,
1994). Blood CD11c+ mDC subsets are considered
‘‘naive’’ cells that are migrating from the bone marrow to
the peripheral tissue. This assumption is based on their
Immunity
Reviewsimmature phenotype and on the fact that DCs do not recir-
culate from peripheral tissue to blood, as suggested by
mouse studies (Austyn et al., 1988; Kupiec-Weglinski
et al., 1988). It is currently believed that blood CD11c+
mDCs locate to the secondary lymphoid organs and pe-
ripheral tissues as resting interstitial DCs and that they
are related to the in vitro generated monocyte-derived or
CD34-derived interstitial DCs (Shortman and Liu, 2002).
mDC lineage-CD4+CD11c+ or CD4CD11c+ cells express
CD45RO, myeloid markers, such as CD13 and CD33, and
the MHC-like molecule CD1c. These phenotypic markers
allow clear distinction of blood mDCs from blood pDCs
(which lack CD11c but express CD123 and BDCA2) and
can be used to purify the two subsets for in vitro studies
(Duramad et al., 2003; Rissoan et al., 1999; Soumelis
et al., 2002). Blood pDCs express L-selectin and migrate
to the secondary lymphoid organs through the high endo-
thelial venules (Yoneyama et al., 2004).
Mousebloodalso contains twopopulations of precursor
DCs. Cells with the surface phenotype CD11c+CD11b+-
CD45RA closely resemble the human immature CD11c+
precursor DCs and rapidly transform into CD8+ cDCs after
TNF-a stimulation. A second population of cells with the
surface phenotype CD11cloCD11bCD45RAhi closely re-
semble human pDCs by morphology and function. On
stimulation with CpG, these cells make large amounts of
type-1 IFNs and rapidly develop into DCs that bear CD8
(O’Keeffe et al., 2003).
Concluding Remarks
DCs represent a cell system consisting of several pheno-
typic and functionally distinct subsets. Although the ulti-
mate origin of all cDCs and pDCs is the BM HSCs, DCs,
unlike other hemopoietic cell lineages, can develop
through either the myeloid or lymphoid pathways from
a Flt3-expressing progenitor (Figure 1). Different transcrip-
tion factors and cytokines play important roles in control-
ling the development of different DC populations with dis-
tinct functional potentials. Although the intrinsic property
of each DC subset may dictate their functional specialty,
their final maturation and the functional capacities are
also influenced by the tissue environments and the cell
types they interacted. A better understanding of the de-
tailed processes governing the development and function
of these DC subsets is essential for future application of
DCs in immune modulation, vaccine design, and immune
therapies.
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